TIDMPRTC
PureTech Health PLC
30 July 2020
30 July 2020
PureTech Health plc
PureTech Founded Entity Vor Biopharma Appoints David Lubner to
its Board of Directors
PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a
clinical-stage biotherapeutics company dedicated to discovering,
developing and commercialising highly differentiated medicines for
devastating diseases, is pleased to note that its Founded Entity,
Vor Biopharma, today announced it has appointed David Lubner to its
Board of Directors. A life science leader and senior finance
executive, Mr Lubner most recently served as executive vice
president and chief financial officer at Ra Pharma until May 2020
following its acquisition by UCB.
The full text of the announcement from Vor is as follows:
Vor Biopharma Appoints David Lubner to its Board of
Directors
CAMBRIDGE, Mass., - July 30, 2020 - Vor Biopharma , an oncology
company pioneering engineered haematopoietic stem cells (eHSCs) for
the treatment of cancer, today announced the appointment of David
Lubner, a senior finance executive with over 25 years of
experience, to Vor's Board of Directors.
"David's expertise as a life sciences leader with a deep
understanding of strategy, finance, capital markets and operations
will benefit us greatly moving forward as we continue to build our
company and platform and develop therapies for patients," said
Robert Ang, MBBS, MBA, Vor's President and Chief Executive
Officer.
Most recently, Mr Lubner served as Executive Vice President and
Chief Financial Officer of Ra Pharma until May 2020 following its
acquisition by UCB. Prior to Ra Pharma, he served as Senior Vice
President and Chief Financial Officer of Tetraphase Pharmaceuticals
and as Chief Financial Officer of PharMetrics Inc., a leading
patient-based pharmacy and medical claims data informatics company.
He was also Chief Financial Officer at ProScript, where Velcade(R)
(bortezomib), a therapy widely used for the treatment of the blood
cancer multiple myeloma, was discovered. Mr Lubner serves on the
Board of Directors of Dyne Therapeutics, Therapeutics Acquisition
Corp. (Nasdaq: TXAC), Gemini Therapeutics and Ichnos Sciences. A
Certified Public Accountant, Mr Lubner received his BS in business
administration from Northeastern University and an MS in taxation
from Bentley University.
"Having just completed a $110 million Series B financing, Vor is
well placed to build out its scientific platform and begin clinical
trials in 2021," Lubner said. "Vor's approach has the potential to
radically change outcomes in patients suffering from acute myeloid
leukaemia and other blood cancers, and I look forward to
contributing towards Vor's success."
About Vor Biopharma
Vor Biopharma aims to transform the lives of cancer patients by
pioneering engineered haematopoietic stem cell (eHSC) therapies. By
removing biologically redundant proteins from eHSCs, these cells
become inherently invulnerable to complementary targeted therapies
while tumour cells are left susceptible, thereby unleashing the
potential of targeted therapies to benefit cancer patients in
need.
Vor's platform could be used to potentially change the treatment
paradigm of both haematopoietic stem cell transplants and targeted
therapies, such as antibody drug conjugates, bispecific antibodies
and CAR-T cell treatments.
Vor is based in Cambridge, Mass. and has a broad intellectual
property base, including in-licenses from Columbia University,
where foundational work was conducted by inventor and Vor
Scientific Board Chair Siddhartha Mukherjee, MD, DPhil.
About VOR33
Vor's lead product candidate, VOR33, consists of engineered
haematopoietic stem cells (eHSCs) that lack the protein CD33. Once
these cells are transplanted into a cancer patient, we believe that
CD33 will become a far more cancer-specific target, potentially
avoiding toxicity to the normal blood and bone marrow associated
with CD33-targeted therapies. Vor aims to improve the therapeutic
window and effectiveness of CD33-targeted therapies, thereby
potentially broadening the clinical benefit to patients suffering
from acute myeloid leukaemia.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercialising highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
is comprised of 24 products and product candidates, including two
that have been cleared by the US Food and Drug Administration
(FDA). All of the underlying programmes and platforms that resulted
in this pipeline of product candidates were initially identified or
discovered and then advanced by the PureTech team through key
validation points based on the Company's unique insights into the
biology of the brain, immune and gut, or BIG, systems and the
interface between those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Stephanie Simon
+1 617 651 3156 +44 (0) 20 3727 1000 +1 617 581 9333
amt@puretechhealth.com ben.atwell@FTIconsulting.com stephanie@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAPPUMUMUPUPWB
(END) Dow Jones Newswires
July 30, 2020 08:02 ET (12:02 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024